Specifically, anti-PD-L1 antibodies stimulate CD8+ T cells to release cytokine IFNγ to activate the JAK-STAT1 pathway in cancer cells, thereby reducing the expressions of SLC7A11 and SLC3A2, and ultimately increasing the sensitivity of cancer cells to ferroptosis (Wang et al., 2019). Here, CD8A is linked to cancer.